Month: April 2022

RT @ThomasCiullaMD: Just published: Disease progression pathways of wet AMD: op…

[ad_1] RT @ThomasCiullaMD: Just published: https://t.co/pGZQQVEySc Disease progression pathways of wet AMD: opportunities for new target discovery… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Looking forward to ARVO 2022 meeting next week. Check out these excellent presen…

[ad_1] Looking forward to ARVO 2022 meeting next week. Check out these excellent presentations providing insights on #suprachoroidal delivery of investigational agents, a corticosteroid, and a #genetherapy. #xipere #uveitis #AMD #diabeticretinopathy #retina #biotech #clinicalresearch https://t.co/havK3tYkqD [ad_2] Source by Thomas Ciulla, MD, MBA Return to main 

RT @ThomasCiullaMD: This webinar on #suprachoroidal delivery features an amazing…

[ad_1]
RT @ThomasCiullaMD: This webinar on #suprachoroidal delivery features an amazingly talented team:
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Just published: This work supports the favorable targeting, compartmentalizatio…

[ad_1] Just published: This work supports the favorable targeting, compartmentalization and durability of the first FDA-approved #suprachoroidal therapy…#eyes #retina #xipere #uveitis https://t.co/LQ0o7aZkmS [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinaToday: How Will Suprachoroidal Injections Alter the Treatment Landscap…

[ad_1] RT @RetinaToday: How Will Suprachoroidal Injections Alter the Treatment Landscape? View more from @EvolveMedEd: https://t.co/NjPvvseOWE htt… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Our clinical study, highlighting the need for better therapy, was picked up by O…

[ad_1]
Our clinical study, highlighting the need for better therapy, was picked up by Ophthalmology Advisor: Longer Term Anti-VEGF Outcomes in Neovascular AMD, Diabetic and Vein Occlusion Related Macular Edema:
#retina #AMD #diabeticretinopathy https://t.co/uUMf8y1V2M
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Our recent paper was “Editor’s Choice”: This post hoc analys…

[ad_1] RT @ThomasCiullaMD: Our recent paper was “Editor’s Choice”: This post hoc analysis compared #suprachoroidal triamcinolone acetonide (CLS-TA… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ModernRetina: @BauschRetina and @clearsidebio are rolling out the new therap…

[ad_1] RT @ModernRetina: @BauschRetina and @clearsidebio are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the t… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinalPhys: Read about the commercial launch of Xipere and more industry ne…

[ad_1]
RT @RetinalPhys: Read about the commercial launch of Xipere and more industry news in the eUpdate: https://t.co/opmf3Pc1D6
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

This webinar on #suprachoroidal delivery features an amazingly talented team: …

[ad_1] This webinar on #suprachoroidal delivery features an amazingly talented team: https://t.co/S0LmnWUSqm [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.